Dihexa vs P21
Comparison of Dihexa (Very Low evidence) and P21 (Very Low evidence).
Last updated: February 12, 2026
Dihexa
P21
Overview
Dihexa and P21 are both studied in the peptide research space.
Dihexa: An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling.
P21: A hexapeptide (Ac-DGGLAG-NH2) derived from ciliary neurotrophic factor (CNTF) that is claimed to mimic BDNF effects and promote neurogenesis.
Evidence Comparison
| Aspect | Dihexa | P21 |
|---|---|---|
| Evidence Level | Very Low | Very Low |
| Human Studies | 0 | 0 |
| Preclinical Studies | 12 | 15 |
| Total Sources | 12 | 15 |
Key Differences
| Aspect | Dihexa | P21 |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Very Low | Very Low |
| Total Sources | 12 | 15 |
| Human Studies | 0 | 0 |
Summary
- Dihexa: Very Low evidence with 12 total sources (0 human)
- P21: Very Low evidence with 15 total sources (0 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.